公开(公告)号：WO2011117328A1

公开(公告)日：2011-09-29

申请号：PCT/EP2011/054503

申请日：2011-03-23

申请人： NETRIS PHARMA ,  MEHLEN, Patrick ,  DELLOYE-BOURGEOIS, Céline ,  BERNET, Agnès ,  DELCROS, Jean Guy ,  NONY, Pascale

发明人： MEHLEN, Patrick ,  DELLOYE-BOURGEOIS, Céline ,  BERNET, Agnès ,  DELCROS, Jean Guy ,  NONY, Pascale

IPC分类号： A61K38/17 ,  A61K39/395 ,  C12N15/11 ,  A61P35/00

CPC分类号： C07K19/00 ,  A61K38/177 ,  A61K2039/505 ,  C07K14/475 ,  C07K16/18 ,  C07K16/22 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/14

摘要： The invention is relative to the use of an effective amount of an agonist of the CDO's apoptotic function for the preparation of a drug to induce cell apoptosis in a patient having tumoral cells bearing CDO and expressing SHH. The agonist may be a CDO fragment, a fusion protein comprising a CDO fragment, an antibody against SHH, or a siRNA which is capable of inhibiting SHH expression. The invention also concerns a pharmaceutical composition containing an agonist of the CDO's apoptotic function or a CDO polypeptide or an antibody specific to CDO, and an agonist of the PTC1's apoptotic function or a PTC1 polypeptide or an antibody specific to PTC1, and a pharmaceutically acceptable excipient or vehicle.

摘要翻译： 本发明是相对于有效量的CDO的凋亡功能激动剂在制备具有携带CDO和表达SHH的肿瘤细胞的患者中诱导细胞凋亡的药物的用途。 激动剂可以是CDO片段，包含CDO片段的融合蛋白，抗SHH的抗体或能够抑制SHH表达的siRNA。 本发明还涉及包含CDO的凋亡功能的激动剂或CDO多肽或对CDO特异性的抗体以及PTC1的凋亡功能的激动剂或PTC1多肽或PTC1特异性抗体的药物组合物和药学上可接受的赋形剂 或车辆。

公开(公告)号：WO2009141440A1

公开(公告)日：2009-11-26

申请号：PCT/EP2009/056252

申请日：2009-05-22

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  CENTRE LEON BERARD ,  ENS - ECOLE NORMALE SUPERIEURE DE LYON ,  UNIVERSITE CLAUDE BERNARD LYON 1 ,  MEHLEN, Patrick ,  BERNET, Agnès ,  DELLOYE, Céline

发明人： MEHLEN, Patrick ,  BERNET, Agnès ,  DELLOYE, Céline

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6809 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136

摘要： The present invention comprises an in vitro method for predicting whether neuroblastoma (NB) identified in a patient is a metastatic and/or an aggressive NB, and/or a NB having a poor prognosis, or for predicting a NB having a good prognosis. The present invention further comprises a method for preventing and/or treating such NB cancer and a method for selecting a therapeutic compound for the prevention or the treatment of such metastatic and/or aggressive NB. Finally, the present invention is directed to a method for determining in vitro the efficiency of an anti-NB cancer treatment or for in vitro selecting patients who respond to a specific anti-NB treatment and wherein said NB cancer is a metastatic and/or aggressive NB related to the presence of an overexpression of netrin-1 in the tumoral tissue.

摘要翻译： 本发明包括用于预测患者中鉴定的成神经细胞瘤（NB）是否具有转移性和/或侵袭性NB，和/或预后不良的NB或用于预测具有良好预后的NB的体外方法。 本发明还包括用于预防和/或治疗这种NB癌症的方法和选择用于预防或治疗这种转移性和/或侵袭性NB的治疗化合物的方法。 最后，本发明涉及用于体外测定抗NB癌症治疗或体外选择对特异性抗NB治疗作出反应的患者的方法，其中所述NB癌症是转移性和/或侵袭性的 NB与肿瘤组织中netrin-1的过度表达有关。

公开(公告)号：WO2007099133A1

公开(公告)日：2007-09-07

申请号：PCT/EP2007/051920

申请日：2007-02-28

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  CENTRE LEON BERARD ,  MEHLEN, Patrick ,  BERNET, Agnès ,  FITAMANT, Julien

发明人： MEHLEN, Patrick ,  BERNET, Agnès ,  FITAMANT, Julien

IPC分类号： G01N33/50 ,  G01N33/566

CPC分类号： C07K16/2863 ,  C07K16/22 ,  C07K2317/732 ,  C07K2317/76 ,  C12Q1/18 ,  G01N33/574 ,  G01N2333/475 ,  G01N2500/02 ,  G01N2800/52

摘要： The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.

摘要翻译： 本发明的主题涉及基于这些化合物与netrin-1受体相互作用和/或抑制netrin-1受体的细胞内结构域的二聚化的能力来筛选抗癌化合物的体外方法， 1受体在肿瘤细胞中表达。 本发明还涉及一种用于预测转移性或侵袭性癌症的存在或基于测量netrin-1的表达水平来确定抗癌治疗效率的方法。 本发明还包括作为用于治疗与肿瘤细胞对netrin-1的过度表达相关的癌症如转移性乳腺癌的药物的试剂盒和化合物。

公开(公告)号：WO2010079230A1

公开(公告)日：2010-07-15

申请号：PCT/EP2010/050233

申请日：2010-01-11

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  CENTRE LEON BERARD ,  ENS - ECOLE NORMALE SUPERIEURE DE LYON ,  MEHLEN, Patrick, Etienne, Roger ,  BERNET, Agnès, Christine ,  DELLOYE, Céline, Jacqueline, Andrée ,  CASTETS-MESTRALLET, Marie, Anne-Sophie, Emmanuelle

发明人： MEHLEN, Patrick, Etienne, Roger ,  BERNET, Agnès, Christine ,  DELLOYE, Céline, Jacqueline, Andrée ,  CASTETS-MESTRALLET, Marie, Anne-Sophie, Emmanuelle

IPC分类号： C07K14/475 ,  G01N33/50

CPC分类号： C07K14/475 ,  G01N33/5017 ,  G01N33/5064 ,  G01N2333/4703 ,  G01N2500/10

摘要： The present invention relates to an in vitro method for selecting a compound capable to induce the death of endothelial cells, preferably endothelial cells from vessels or neovessels. The invention further comprises the use of netrin-1 function inhibitors as compounds capable to induce the death of endothelial cells, preferably endothelial cells from vessels or neovessels of tumor expressing netrin-1. Finally, the invention relates to a kit for the selection of a compound capable to induce the death of endothelial cells.

摘要翻译： 本发明涉及用于选择能够诱导内皮细胞（优选来自血管或新血管内皮细胞）死亡的化合物的体外方法。 本发明还包括使用netrin-1功能抑制剂作为能够诱导内皮细胞死亡的化合物，优选来自表达netrin-1的肿瘤的血管或新血管的内皮细胞。 最后，本发明涉及用于选择能够诱导内皮细胞死亡的化合物的试剂盒。